Drug Profile
Robatumumab
Alternative Names: 19D12; SCH 717454; SCHOOL 717454Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Schering-Plough
- Developer Merck & Co; Schering-Plough
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Insulin-like growth factor-I receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Colorectal cancer; Osteosarcoma; Sarcoma; Solid tumours
Most Recent Events
- 01 Aug 2013 Merck terminates its phase II trial for Osteosarcoma or Ewing's sarcoma in USA, Canada, European Union & South Amercia (NCT00617890)
- 15 Apr 2010 Merck completes enrolment in its phase I trial for Solid tumours in USA
- 15 Dec 2009 Phase-II clinical trials in Solid tumours (combination therapy in adults) in USA (IV)